Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

Ming Lun Yeh; Chao Hung Hung; Kuo Chih Tseng; Hsueh Chou Lai; Chi Yi Chen; Hsing Tao Kuo; Jing Houng Wang; Jyh Jou Chen; Pei Lun Lee; Rong Nan Chien; Chi Chieh Yang; Gin Ho Lo; Chi Ming Tai; Chih Wen Lin; Jia Horng Kao; Chen Hua Liu; Sheng Lei Yan; Ming Jong Bair; Chun Yen Lin; Wei Wen Su; Cheng Hsin Chu; Chih Jen Chen; Shui Yi Tung; Ching Chu Lo; Pin Nan Cheng; Yen Cheng Chiu; Chia Chi Wang; Jin Shiung Cheng; Wei Lun Tsai; Han Chieh Lin; Yi Hsiang Huang; Chung Feng Huang; Jee Fu Huang; Chia Yen Dai; Wan Long Chuang; Pei Chien Tsai; Cheng Yuan Peng; Chun Jen Liu; Ming Lung Yu

doi:10.1007/s12072-021-10220-8

Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

Ming Lun Yeh, Chao Hung Hung, Kuo Chih Tseng, Hsueh Chou Lai, Chi Yi Chen, Hsing Tao Kuo, Jing Houng Wang, Jyh Jou Chen, Pei Lun Lee, Rong Nan Chien, Chi Chieh Yang, Gin Ho Lo, Chi Ming Tai, Chih Wen Lin, Jia Horng Kao, Chen Hua Liu, Sheng Lei Yan, Ming Jong Bair, Chun Yen Lin, Wei Wen SuCheng Hsin Chu, Chih Jen Chen, Shui Yi Tung, Ching Chu Lo, Pin Nan Cheng, Yen Cheng Chiu, Chia Chi Wang, Jin Shiung Cheng, Wei Lun Tsai, Han Chieh Lin, Yi Hsiang Huang, Chung Feng Huang, Jee Fu Huang, Chia Yen Dai, Wan Long Chuang, Pei Chien Tsai, Cheng Yuan Peng, Chun Jen Liu, Ming Lung Yu

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Background and aim: The long-term outcome of hepatitis B virus (HBV) infection among patients dually infected with HBV and hepatitis C virus (HCV) remains unclear. We aimed to investigate the long-term liver outcomes of HBV/HCV-coinfected patients after antiviral therapy. Methods: A total of 11,359 chronically HCV-infected patients with interferon-based therapy were registered in a nationwide Taiwanese Chronic Hepatitis C Cohort. A propensity score matched (PSM) cohort of HCV mono-infected (n = 7020) and HBV/HCV (n = 702) co-infected patients by age, sex, and fibrosis was recruited for outcome analysis. The primary outcome was liver-related complications, including hepatocellular carcinoma (HCC) and liver decompensation during a mean follow-up period of 4.44 years. Results: Among HBV/HCV co-infected patients, patients without HCV-SVR had a significantly higher 10-year cumulative incidence of major liver-related complications than those with HCV-SVR. However, among patients with HCV-SVR in the PSM cohort, the risk of major liver-related complications, both HCC and liver decompensation, did not differ between HBV/HCV co-infected and HCV mono-infected patients. Similar results were observed among those without HCV-SVR. A substantial lower risk of major liver-related complications was found in HBV/HCV co-infected patients with HCV SVR and subsequent anti-HBV nucleot(s)ide analogues treatment. Overall, factors associated with major liver-related complications included age ≥ 65 year-old, BMI ≥ 27 kg/m², FIB-4 ≥ 3.25, eGFR < 60 ml/min/1.73 m², and non-HCV SVR, but not HBV co-infection. Conclusion: Interferon-based therapy reduced the long-term risk of major liver-related complications among HBV/HCV co-infected patients, as among HCV mono-infected patients. Nevertheless, post-HCV-SVR surveillance for major liver-related complications is mandatory among those high-risk groups.

Original language	English
Pages (from-to)	1109-1121
Number of pages	13
Journal	Hepatology International
Volume	15
Issue number	5
DOIs	https://doi.org/10.1007/s12072-021-10220-8
Publication status	Published - 2021 Oct

All Science Journal Classification (ASJC) codes

Hepatology

Access to Document

10.1007/s12072-021-10220-8

Cite this

Yeh, M. L., Hung, C. H., Tseng, K. C., Lai, H. C., Chen, C. Y., Kuo, H. T., Wang, J. H., Chen, J. J., Lee, P. L., Chien, R. N., Yang, C. C., Lo, G. H., Tai, C. M., Lin, C. W., Kao, J. H., Liu, C. H., Yan, S. L., Bair, M. J., Lin, C. Y., ... Yu, M. L. (2021). Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). Hepatology International, 15(5), 1109-1121. https://doi.org/10.1007/s12072-021-10220-8

@article{e96d53ed3e944e6ca22228a510205b08,

title = "Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)",

abstract = "Background and aim: The long-term outcome of hepatitis B virus (HBV) infection among patients dually infected with HBV and hepatitis C virus (HCV) remains unclear. We aimed to investigate the long-term liver outcomes of HBV/HCV-coinfected patients after antiviral therapy. Methods: A total of 11,359 chronically HCV-infected patients with interferon-based therapy were registered in a nationwide Taiwanese Chronic Hepatitis C Cohort. A propensity score matched (PSM) cohort of HCV mono-infected (n = 7020) and HBV/HCV (n = 702) co-infected patients by age, sex, and fibrosis was recruited for outcome analysis. The primary outcome was liver-related complications, including hepatocellular carcinoma (HCC) and liver decompensation during a mean follow-up period of 4.44 years. Results: Among HBV/HCV co-infected patients, patients without HCV-SVR had a significantly higher 10-year cumulative incidence of major liver-related complications than those with HCV-SVR. However, among patients with HCV-SVR in the PSM cohort, the risk of major liver-related complications, both HCC and liver decompensation, did not differ between HBV/HCV co-infected and HCV mono-infected patients. Similar results were observed among those without HCV-SVR. A substantial lower risk of major liver-related complications was found in HBV/HCV co-infected patients with HCV SVR and subsequent anti-HBV nucleot(s)ide analogues treatment. Overall, factors associated with major liver-related complications included age ≥ 65 year-old, BMI ≥ 27 kg/m2, FIB-4 ≥ 3.25, eGFR < 60 ml/min/1.73 m2, and non-HCV SVR, but not HBV co-infection. Conclusion: Interferon-based therapy reduced the long-term risk of major liver-related complications among HBV/HCV co-infected patients, as among HCV mono-infected patients. Nevertheless, post-HCV-SVR surveillance for major liver-related complications is mandatory among those high-risk groups.",

author = "Yeh, {Ming Lun} and Hung, {Chao Hung} and Tseng, {Kuo Chih} and Lai, {Hsueh Chou} and Chen, {Chi Yi} and Kuo, {Hsing Tao} and Wang, {Jing Houng} and Chen, {Jyh Jou} and Lee, {Pei Lun} and Chien, {Rong Nan} and Yang, {Chi Chieh} and Lo, {Gin Ho} and Tai, {Chi Ming} and Lin, {Chih Wen} and Kao, {Jia Horng} and Liu, {Chen Hua} and Yan, {Sheng Lei} and Bair, {Ming Jong} and Lin, {Chun Yen} and Su, {Wei Wen} and Chu, {Cheng Hsin} and Chen, {Chih Jen} and Tung, {Shui Yi} and Lo, {Ching Chu} and Cheng, {Pin Nan} and Chiu, {Yen Cheng} and Wang, {Chia Chi} and Cheng, {Jin Shiung} and Tsai, {Wei Lun} and Lin, {Han Chieh} and Huang, {Yi Hsiang} and Huang, {Chung Feng} and Huang, {Jee Fu} and Dai, {Chia Yen} and Chuang, {Wan Long} and Tsai, {Pei Chien} and Peng, {Cheng Yuan} and Liu, {Chun Jen} and Yu, {Ming Lung}",

note = "Publisher Copyright: {\textcopyright} 2021, Asian Pacific Association for the Study of the Liver.",

year = "2021",

month = oct,

doi = "10.1007/s12072-021-10220-8",

language = "English",

volume = "15",

pages = "1109--1121",

journal = "Hepatology International",

issn = "1936-0533",

publisher = "Springer New York",

number = "5",

}

Yeh, ML, Hung, CH, Tseng, KC, Lai, HC, Chen, CY, Kuo, HT, Wang, JH, Chen, JJ, Lee, PL, Chien, RN, Yang, CC, Lo, GH, Tai, CM, Lin, CW, Kao, JH, Liu, CH, Yan, SL, Bair, MJ, Lin, CY, Su, WW, Chu, CH, Chen, CJ, Tung, SY, Lo, CC, Cheng, PN , Chiu, YC, Wang, CC, Cheng, JS, Tsai, WL, Lin, HC, Huang, YH, Huang, CF, Huang, JF, Dai, CY, Chuang, WL, Tsai, PC, Peng, CY, Liu, CJ & Yu, ML 2021, 'Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)', Hepatology International, vol. 15, no. 5, pp. 1109-1121. https://doi.org/10.1007/s12072-021-10220-8

Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). / Yeh, Ming Lun; Hung, Chao Hung; Tseng, Kuo Chih et al.
In: Hepatology International, Vol. 15, No. 5, 10.2021, p. 1109-1121.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy

T2 - a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

AU - Yeh, Ming Lun

AU - Hung, Chao Hung

AU - Tseng, Kuo Chih

AU - Lai, Hsueh Chou

AU - Chen, Chi Yi

AU - Kuo, Hsing Tao

AU - Wang, Jing Houng

AU - Chen, Jyh Jou

AU - Lee, Pei Lun

AU - Chien, Rong Nan

AU - Yang, Chi Chieh

AU - Lo, Gin Ho

AU - Tai, Chi Ming

AU - Lin, Chih Wen

AU - Kao, Jia Horng

AU - Liu, Chen Hua

AU - Yan, Sheng Lei

AU - Bair, Ming Jong

AU - Lin, Chun Yen

AU - Su, Wei Wen

AU - Chu, Cheng Hsin

AU - Chen, Chih Jen

AU - Tung, Shui Yi

AU - Lo, Ching Chu

AU - Cheng, Pin Nan

AU - Chiu, Yen Cheng

AU - Wang, Chia Chi

AU - Cheng, Jin Shiung

AU - Tsai, Wei Lun

AU - Lin, Han Chieh

AU - Huang, Yi Hsiang

AU - Huang, Chung Feng

AU - Huang, Jee Fu

AU - Dai, Chia Yen

AU - Chuang, Wan Long

AU - Tsai, Pei Chien

AU - Peng, Cheng Yuan

AU - Liu, Chun Jen

AU - Yu, Ming Lung

PY - 2021/10

Y1 - 2021/10

N2 - Background and aim: The long-term outcome of hepatitis B virus (HBV) infection among patients dually infected with HBV and hepatitis C virus (HCV) remains unclear. We aimed to investigate the long-term liver outcomes of HBV/HCV-coinfected patients after antiviral therapy. Methods: A total of 11,359 chronically HCV-infected patients with interferon-based therapy were registered in a nationwide Taiwanese Chronic Hepatitis C Cohort. A propensity score matched (PSM) cohort of HCV mono-infected (n = 7020) and HBV/HCV (n = 702) co-infected patients by age, sex, and fibrosis was recruited for outcome analysis. The primary outcome was liver-related complications, including hepatocellular carcinoma (HCC) and liver decompensation during a mean follow-up period of 4.44 years. Results: Among HBV/HCV co-infected patients, patients without HCV-SVR had a significantly higher 10-year cumulative incidence of major liver-related complications than those with HCV-SVR. However, among patients with HCV-SVR in the PSM cohort, the risk of major liver-related complications, both HCC and liver decompensation, did not differ between HBV/HCV co-infected and HCV mono-infected patients. Similar results were observed among those without HCV-SVR. A substantial lower risk of major liver-related complications was found in HBV/HCV co-infected patients with HCV SVR and subsequent anti-HBV nucleot(s)ide analogues treatment. Overall, factors associated with major liver-related complications included age ≥ 65 year-old, BMI ≥ 27 kg/m2, FIB-4 ≥ 3.25, eGFR < 60 ml/min/1.73 m2, and non-HCV SVR, but not HBV co-infection. Conclusion: Interferon-based therapy reduced the long-term risk of major liver-related complications among HBV/HCV co-infected patients, as among HCV mono-infected patients. Nevertheless, post-HCV-SVR surveillance for major liver-related complications is mandatory among those high-risk groups.

AB - Background and aim: The long-term outcome of hepatitis B virus (HBV) infection among patients dually infected with HBV and hepatitis C virus (HCV) remains unclear. We aimed to investigate the long-term liver outcomes of HBV/HCV-coinfected patients after antiviral therapy. Methods: A total of 11,359 chronically HCV-infected patients with interferon-based therapy were registered in a nationwide Taiwanese Chronic Hepatitis C Cohort. A propensity score matched (PSM) cohort of HCV mono-infected (n = 7020) and HBV/HCV (n = 702) co-infected patients by age, sex, and fibrosis was recruited for outcome analysis. The primary outcome was liver-related complications, including hepatocellular carcinoma (HCC) and liver decompensation during a mean follow-up period of 4.44 years. Results: Among HBV/HCV co-infected patients, patients without HCV-SVR had a significantly higher 10-year cumulative incidence of major liver-related complications than those with HCV-SVR. However, among patients with HCV-SVR in the PSM cohort, the risk of major liver-related complications, both HCC and liver decompensation, did not differ between HBV/HCV co-infected and HCV mono-infected patients. Similar results were observed among those without HCV-SVR. A substantial lower risk of major liver-related complications was found in HBV/HCV co-infected patients with HCV SVR and subsequent anti-HBV nucleot(s)ide analogues treatment. Overall, factors associated with major liver-related complications included age ≥ 65 year-old, BMI ≥ 27 kg/m2, FIB-4 ≥ 3.25, eGFR < 60 ml/min/1.73 m2, and non-HCV SVR, but not HBV co-infection. Conclusion: Interferon-based therapy reduced the long-term risk of major liver-related complications among HBV/HCV co-infected patients, as among HCV mono-infected patients. Nevertheless, post-HCV-SVR surveillance for major liver-related complications is mandatory among those high-risk groups.

UR - http://www.scopus.com/inward/record.url?scp=85112659381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85112659381&partnerID=8YFLogxK

U2 - 10.1007/s12072-021-10220-8

DO - 10.1007/s12072-021-10220-8

M3 - Article

C2 - 34365587

AN - SCOPUS:85112659381

SN - 1936-0533

VL - 15

SP - 1109

EP - 1121

JO - Hepatology International

JF - Hepatology International

IS - 5

ER -

Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this